论文部分内容阅读
以￣（３５）Ｓ标记抗人脑胶质瘤单克隆抗体ＳＺ３９制备成免疫导向放疗剂，在荷人脑胶质瘤裸小鼠体内药代动力学符合三室线性模型，总药时方程为Ｃ＿ｔ＝１５５９２７６ｅ￣（─３．４９ｔ）＋９７７３１３ｅ￣（－０．５ｔ）＋２１６８２ｅ￣（－０．０１７ｔ），Ｔ１／２ａ为０．２３ｈ，Ｔ１／２β为１．４Ｇｈ，Ｔ１／２γ为４２．９ｈ。体内分布研究表明￣（３５）Ｓ－ＭＡｂＳＺ３９可特异性浓聚于胶质瘤，在正常组织中无明显蓄积，发挥了单抗导向的高选择性作用，在给药后第五天，与￣（３５）Ｓ－ｎｌｇＧ及￣（３５）Ｓ相比，特异指数分别为４．１和４．８７，具有显著优越性（Ｐ＞０．０５）。结果揭示３５Ｓ－ＭＡｂＳＺ３９有望作为一种高效低毒的导向放疗制剂应用于胶质瘤治疗，以一周间隔多疗程治疗方案为佳。
The anti-human glioma monoclonal antibody SZ39 was labeled with ~ (35) S to prepare an immunotherapy-directed radiotherapeutic agent. The pharmacokinetics of the human glioma-bearing nude mice were in accordance with the three-compartment linear model with a total drug time of C_t = 1559276e ~ (─3.49t) + 977313e ~ (-0.5t) + 21682e ~ (-0.017t), T1 / 2a was 0.23h, T1 / 2β was 1.4Gh and T1 / 2γ was 42.9h. In vivo distribution studies showed that ~ (35) S-MAbSZ39 could specifically accumulate in gliomas without obvious accumulation in normal tissues and exert the highly selective effect of MAb. On the fifth day after administration, (35) S-nlgG and ~ (35) S, the specific index was 4.1 and 4.87, with significant advantages (P> 0.05). The results revealed that 35S-MAbSZ39 is expected to be used as a highly effective and low toxic targeted radiotherapy in glioma treatment.